a) All submissions must be made electronically using the online system available on the congress website under Scientific Abstracts Guidelines – CBCD 2025, starting January 28, 2025.
b) Single submission phase: Authors must upload the complete work, including photos and tables (if applicable), in their restricted area within the system, following the instructions and limits specified in the online form. The submission deadline is February 20, 2025.
c) Selected and accepted papers will be displayed in the E-Poster Session during the Congress, from April 24 to 27, 2025.
d) Oral Presentation: Among the selected and accepted papers, three (one from each category) will also be chosen for an Oral Presentation at the Congress. These will not necessarily be the award-winning papers.
e) Submission completion requires the upload of a patient consent form for the use of their images in scientific presentations. This must be submitted through the same platform—please check the upload icon.
f) Only papers written in Portuguese will be accepted.
g) At least one of the authors must be a current SBCD member in good standing and must be registered for the 35th CBCD under one of the registration categories (except as an accompanying guest) at the time of submission. Otherwise, the paper may be disqualified.
h) Each submission must have one primary author (specified separately) and up to five co-authors, totaling a maximum of six participants per paper.
The primary author will be legally responsible for the paper and will be credited with any award, should the paper be a winner.
The primary author must designate a corresponding author to receive all communications from the Organizing Committee, unless they take on this role themselves.
The presenter can be any of the co-authors, except for students, and must be indicated in the appropriate field.
i) Students may not submit papers as primary authors or serve as presenters for scientific papers.
The top three papers in each category (except the Popular Jury Award, which is a single prize) will receive awards from the 35th Brazilian Congress of Dermatologic Surgery.
Prof. Dr. Ival Peres Rosa Award
Category: Dissertation/Thesis
1st place: R$ 7,000
2nd place: R$ 5,000
3rd place: R$ 3,500
Prof. Dr. Carlos D’Apparecida S. Machado Filho Award
Category: Research Studies
1st place: R$ 5,500
2nd place: R$ 3,500
3rd place: R$ 2,500
Prof. Dr. Eugênio Raul de Almeida Pimentel Award (SP)
Category: Case Reports
1st place: R$ 4,500
2nd place: R$ 2,500
3rd place: R$ 1,500
Popular Jury Award
Category: Popular Jury
Presented by: Prof. Dr. Ariene Paixão & Prof. Dr. Mauro Enokihara (SP)
Single Prize: R$ 3,000
Note: Prize amounts are gross values.
a) Dissertation/Thesis
Original and unpublished work derived from a master’s dissertation or doctoral thesis, already defended or completed.
b) Research Studies
Original and unpublished research, including:
c) Case Reports
Report of one or more unique cases with a justified reason for presentation, such as:
Authors must select the field of study that best aligns with the nature of their work.
The title must be clear and informative, allowing for a proper understanding of the study's subject. It must not include institutional or author information to ensure anonymity during the evaluation process.
The title should not contain abbreviations that are not standardized in dermatological literature. The character limit is 200 characters.
Any form of sponsorship, support, or personal interest from any of the authors that is directly related to the study and its results must be disclosed.
A 500-character space is available for declaring conflicts of interest.
If no conflicts exist, a clear statement must be included in the designated field, such as: "No conflicts of interest."
Authors must provide the names of the institutions and cities involved in the study.
These details must not appear in the clinical history or any other section that could identify the study, except in this dedicated registration field.
The primary author must designate a corresponding author who will receive all communications from the Organizing Committee.
If the primary author is not the presenter, another group member must be assigned as the presenter in the designated field.
Each submission may include up to six participants:
1 Primary Author
1 Corresponding Author
1 Presenter
Up to 4 Co-authors
For each author, the following details must be provided:
Full name
Role (primary author, corresponding author, presenter, co-authors)
Institutional affiliation at the time of the study
Order of co-authors
Additional Guidelines:
Each primary author may submit a maximum of five papers. After reaching this limit, they may only be listed as a co-author on additional submissions.
A separate electronic form must be used for each submission.
Important: Submissions that are incomplete, have undefined results or conclusions, or include statements such as "results will be presented later" will not be accepted for review and will be disqualified.
The complete body of the paper must be structured according to its category and have a maximum of 5,000 characters, including spaces and punctuation.
A separate field is available in the online submission system for bibliographic references, with a 1,000-character limit.
References must be current, relevant, and formatted in Vancouver style.
Important:
Submissions that lack a full-text body or contain identifiable author or institutional information will be disqualified.
Justification for presenting the case, such as rarity, unusual clinical aspects, atypical progression, or innovative diagnostic and therapeutic approaches, supported by a literature review.
Identification details (excluding patient initials), age, gender.
Clinical history and manifestations.
Laboratory tests confirming the diagnosis.
Therapeutic approach and clinical progression.
Description of the diagnostic or therapeutic method used.
Explanation of clinical and laboratory findings.
Diagnostic certainty and alternative hypotheses.
Advantages and disadvantages of the diagnostic or therapeutic method used.
Maximum of five references, formatted in Vancouver style.
Current state of knowledge on the topic.
Study objectives.
Clear statement of the study’s purpose.
Materials/sample population.
Research methods and statistical analysis.
Ethics committee approval (mandatory for interventional studies).
Key findings of the study.
Comparison of results with existing literature.
Study limitations.
Maximum of five references, formatted in Vancouver style.
Failure to comply with the following guidelines will result in disqualification:
Do not include:
Non-standard abbreviations in dermatological literature.
Reference numbers within the main text.
Patient-identifying details (e.g., initials).
Institution or author names anywhere in the main text.
The online submission system provides a dedicated space for submitting illustrations (figures, photographs, graphs, and tables) to enhance the evaluation of the full paper.
A maximum of six illustrations per submission is allowed, in JPG format, and each must include a title or caption.
Image quality, patient anonymity, and the clarity of tables and graphs will be specifically evaluated and will impact the final score of the submission.
Figures, graphs, or tables must not contain any information identifying the author or institution.
Failure to comply will result in disqualification.
The full paper must be submitted by February 20, 2025 (final deadline).
The corresponding author does not need to submit the complete paper at once. They may return to the system multiple times to edit or complete the submission until marking it as final, as long as it is done before the deadline.
Once finalized, no further changes can be made (including author information). Authors must double-check all details before completing the submission.
After submission, check your email for a confirmation message. If you do not receive it, check your spam folder. This email is proof of submission.
Submissions not finalized by the deadline (February 20, 2025) will not be considered for evaluation.
Papers that do not comply with the guidelines will not be reviewed.
Do not submit duplicate or incomplete papers due to inattention or incorrect system use.
Follow on-screen instructions carefully when navigating the submission system.
The system will display each required formatting step according to the Scientific Paper Evaluation Committee of the 35th CBCD.
For questions, contact the Congress Executive Office at temalivre@criarte.net
All submitted papers will undergo an anonymous review process based on their electronic submission before the congress.
The Scientific Paper Evaluation Committee of the 35th CBCD will verify each submission and forward it to three reviewers from related fields of expertise. These reviewers will anonymously evaluate the papers blindly, using a standardized scoring form based on the following criteria:
Originality
Presentation
Methodology
Scientific/Social Contribution
In the event of a tie, the following criteria will be considered, in order of priority:
Overall evaluation
Relevance of the study
Results and discussion
Methods
Illustrations/Figures/Tables
Introduction
Abstract
Title
References
Final tie-breaker by lottery
To ensure fairness, reviewers will not receive submissions from their own institutions or cities, and members of the Scientific Paper Evaluation Committee will not distribute submissions from their own institutions.
The final score will be calculated as the corrected average of the three reviewers' scores.
The decision of the Scientific Paper Evaluation Committee is final and non-appealable. Authors acknowledge that no appeals regarding the review process will be considered for any submission to the 35th CBCD 2025.
The average of the three reviewers' scores will determine the classification for:
E-poster selection
Award consideration
Additionally, the Scientific Paper Committee will select three papers (one per category) for oral presentation as part of the official congress program.
Papers selected for oral presentation are not necessarily award-winning papers.
A submission will be disqualified if two or more reviewers decide so.
Three selected papers (one per category) will be presented orally in an exclusive session during the 35th CBCD.
Authors must prepare a PowerPoint presentation, even if they have already prepared an e-poster version.
Notification of the presentation date and time will be sent by March 26, 2025, via email to the corresponding author.
All selected papers will be displayed as E-posters on TV screens in a designated area during the congress.
Selected E-posters will compete for the Jury's Popular Choice Award.
Final deadline for E-poster submission: April 7, 2025.
Authors of selected E-posters will be notified via email.
Submission period: March 19 – April 7, 2025.
Accepted file format: JPEG (avoid maximum compression to prevent distortion).
Dimensions: 1080 pixels (width) x 1920 pixels (height) (Full HD).
Single-page format (one-screen layout).
Margins: Maintain at least 50 pixels on all sides to prevent cutoff by TV frames.
Authors may use any graphic editor (e.g., CorelDraw, Adobe Photoshop, PowerPoint).
A step-by-step guide for PowerPoint users is available for those unfamiliar with graphic software.
IMPORTANT:
Failure to submit the E-poster within the deadline will disqualify the presentation from being exhibited.
Authors selected for ORAL PRESENTATION will be notified by March 26, 2025.
Files must be prepared according to the following guidelines and submitted in the Media-Desk Room at least 1 hour before the presentation.
PowerPoint Requirements:
File format: .ppt/.pptx
Maximum slides: 12
File size limit: 10MB
Presentation time: 5 minutes
Slide Structure:
Title Slide: Title, Authors, Institution, Conflict of Interest declaration (if applicable).
Conflict of Interest (if any) – disclose funding, support, or affiliations.
Main Content: Case Identification, Clinical History, Diagnostic Methods, Treatment & Evolution, with images (clinical, histopathological, etc.).
Final Slide: References.
Formatting Tips:
Recommended: White background, black text, University/Institution logo.
Use images from submission & additional relevant visuals.
PowerPoint Requirements:
File format: .ppt/.pptx
Maximum slides: 12
File size limit: 10MB
Presentation time: 10 minutes
Slide Structure:
Title Slide: Title, Authors, Institution, Conflict of Interest declaration (if applicable).
Conflict of Interest (if any) – disclose funding, support, or affiliations.
Main Content: Introduction, Objectives, Materials/Methods, Results, Discussion, Conclusion.
Final Slide: References.
Formatting Tips:
Recommended: White background, black text, University/Institution logo.
Include tables, graphs, clinical & histopathological images (if relevant).
IMPORTANT: Files must be submitted at least 1 hour before the presentation at the Media-Desk Room to ensure proper projection setup.
All selected oral presentations will receive an Oral Presentation Certificate.
The electronic submission platform opens on January 28, 2025.
Submissions are exclusively online via the official congress website: cbcd2025.com.br.
Submissions via other means will NOT be accepted.
Deadline: February 20, 2025, at 11:59 PM (Brasília time).
Questions about submission & electronic forms? Contact: temalivre@criarte.net (mention "CBCD 2025" in the subject).
Submitted works will be published EXACTLY as received—no revisions by the congress committee.
Authors are responsible for correct writing & formatting.
No modifications (title, authorship, text, or illustrations) are allowed after submission.
Authors must declare any financial support or sponsorships.
All drugs & products must be cited by their generic names.
Promotional material from sponsors is NOT allowed.
No announcements implying endorsement by the CBCD 2025 or the Brazilian Society of Dermatologic Surgery will be permitted.
Certificates will be available electronically on the congress website within 7 business days after the event ends.
One certificate will be issued per work (not per author).
